Last reviewed · How we verify

China-approved Bevacizumab — Competitive Intelligence Brief

China-approved Bevacizumab (China-approved Bevacizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody). Area: Oncology.

phase 3 VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor) Oncology Biologic Live · refreshed every 30 min

Target snapshot

China-approved Bevacizumab (China-approved Bevacizumab) — Zhejiang Teruisi Pharmaceutical Inc.. Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting tumor angiogenesis and reducing blood supply to cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
China-approved Bevacizumab TARGET China-approved Bevacizumab Zhejiang Teruisi Pharmaceutical Inc. phase 3 VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Bev) Bevacizumab (Bev) Eli Lilly and Company marketed VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)
Intravitreal Bevacizumab IVB Intravitreal Bevacizumab IVB Khyber Teaching Hospital marketed VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)
Intravitreal bevacizumab Intravitreal bevacizumab University of Sao Paulo marketed VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)
Bevacizumab (Avastin®) Bevacizumab (Avastin®) Hanny Al-Samkari, MD marketed VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)
Intravitreal injection of bevacizumab Intravitreal injection of bevacizumab Barnes Retina Institute marketed VEGF inhibitor (monoclonal antibody) VEGF (vascular endothelial growth factor)
Subconjunctival Bevacizumab Subconjunctival Bevacizumab Grewal Eye Institute marketed VEGF inhibitor (monoclonal antibody) VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody) class)

  1. Institut de Recherches Internationales Servier · 2 drugs in this class
  2. Bio-Thera Solutions · 1 drug in this class
  3. Centus Biotherapeutics Limited · 1 drug in this class
  4. Cipla BioTec Pvt. Ltd. · 1 drug in this class
  5. Eli Lilly and Company · 1 drug in this class
  6. Grewal Eye Institute · 1 drug in this class
  7. Hanny Al-Samkari, MD · 1 drug in this class
  8. Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · 1 drug in this class
  9. Khyber Teaching Hospital · 1 drug in this class
  10. Mylan Pharmaceuticals Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). China-approved Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/china-approved-bevacizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: